Sanofi (NYSE:SNY) today touted data from the Take Control trial of its Toujeo insulin glargine product in patients with Type II diabetes.
The study compared patients using Toujeo with a titration algorithm managed by the patient, compared to patients whose dose adjustment was decided by their physicians.
The 631-patient trial revealed that after six months, patients with Type II diabetes who used patient-driven titration experienced improvement in HbA1c levels compared with patients who followed physician-driven titration.
The proportion of patients who reached the pre-determined blood glucose target without experiencing hypoglycemia was 67.5% in the patient-driven titration group, while 58.4% in the group using physician-driven titration met the target without hypoglycemia.
Similar proportions of patients in both groups had at least one severe or confirmed hypoglycemic event, the company reported. Full results from the trial are slated to be announced next year.
“The results of the Take Control study demonstrate that patients can make a critical contribution to work toward their own effective blood sugar target when they are well trained and using a basal insulin such as Toujeo,” Riccardo Perfetti, Sanofi’s VP of DCV medical affairs, said in prepared remarks.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
